Samuel O. Purvine
Pacific Northwest National Laboratory
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Samuel O. Purvine.
Nature Genetics | 2003
Jeffrey A. Ranish; Eugene C. Yi; Deena M. Leslie; Samuel O. Purvine; David R. Goodlett; Jimmy K. Eng; Ruedi Aebersold
We describe a generic strategy for determining the specific composition, changes in the composition, and changes in the abundance of protein complexes. It is based on the use of isotope-coded affinity tag (ICAT) reagents and mass spectrometry to compare the relative abundances of tryptic peptides derived from suitable pairs of purified or partially purified protein complexes. In a first application, the genuine protein components of a large RNA polymerase II (Pol II) preinitiation complex (PIC) were distinguished from a background of co-purifying proteins by comparing the relative abundances of peptides derived from a control sample and the specific complex that was purified from nuclear extracts by a single-step promoter DNA affinity procedure. In a second application, peptides derived from immunopurified STE12 protein complexes isolated from yeast cells in different states were used to detect quantitative changes in the abundance of the complexes, and to detect dynamic changes in the composition of the samples. The use of quantitative mass spectrometry to guide identification of specific complex components in partially purified samples, and to detect quantitative changes in the abundance and composition of protein complexes, provides the researcher with powerful new tools for the comprehensive analysis of macromolecular complexes.
Molecular Systems Biology | 2010
Nathan E. Lewis; Kim K. Hixson; Tom M Conrad; Joshua A. Lerman; Pep Charusanti; Ashoka D. Polpitiya; Joshua N. Adkins; Gunnar Schramm; Samuel O. Purvine; Daniel Lopez-Ferrer; Karl K. Weitz; Roland Eils; Rainer König; Richard D. Smith; Bernhard O. Palsson
After hundreds of generations of adaptive evolution at exponential growth, Escherichia coli grows as predicted using flux balance analysis (FBA) on genome‐scale metabolic models (GEMs). However, it is not known whether the predicted pathway usage in FBA solutions is consistent with gene and protein expression in the wild‐type and evolved strains. Here, we report that >98% of active reactions from FBA optimal growth solutions are supported by transcriptomic and proteomic data. Moreover, when E. coli adapts to growth rate selective pressure, the evolved strains upregulate genes within the optimal growth predictions, and downregulate genes outside of the optimal growth solutions. In addition, bottlenecks from dosage limitations of computationally predicted essential genes are overcome in the evolved strains. We also identify regulatory processes that may contribute to the development of the optimal growth phenotype in the evolved strains, such as the downregulation of known regulons and stringent response suppression. Thus, differential gene and protein expression from wild‐type and adaptively evolved strains supports observed growth phenotype changes, and is consistent with GEM‐computed optimal growth states.
Omics A Journal of Integrative Biology | 2002
Andrew Keller; Samuel O. Purvine; Alexey I. Nesvizhskii; Sergey Stolyar; David R. Goodlett; Eugene Kolker
Several methods have been used to identify peptides that correspond to tandem mass spectra. In this work, we describe a data set of low energy tandem mass spectra generated from a control mixture of known protein components that can be used to evaluate the accuracy of these methods. As an example, these spectra were searched by the SEQUEST application against a human peptide sequence database. The numbers of resulting correct and incorrect peptide assignments were then determined. We show how the sensitivity and error rate are affected by the use of various filtering criteria based upon SEQUEST scores and the number of tryptic termini of assigned peptides.
Molecular & Cellular Proteomics | 2006
Tao Liu; Wei Jun Qian; Heather M. Mottaz; Marina A. Gritsenko; Angela D. Norbeck; Ronald J. Moore; Samuel O. Purvine; David G. Camp; Richard D. Smith
Strategies for removal of high abundance proteins have been increasingly utilized in proteomic studies of serum/plasma and other body fluids to enhance the detection of low abundance proteins and achieve broader proteome coverage; however, both the reproducibility and specificity of the high abundance protein depletion process still represent common concerns. Here we report a detailed evaluation of immunoaffinity subtraction performed applying the ProteomeLab IgY-12 system that is commonly used in human serum/plasma proteome characterization in combination with high resolution LC-MS/MS. Plasma samples were repeatedly processed using this approach, and the resulting flow-through fractions and bound fractions were individually analyzed for comparison. The removal of target proteins by the immunoaffinity subtraction system and the overall process was highly reproducible. Non-target proteins, including one spiked protein standard (rabbit glyceraldehyde-3-phosphate dehydrogenase), were also observed to bind to the column at different levels but also in a reproducible manner. The results suggest that multiprotein immunoaffinity subtraction systems can be readily integrated into quantitative strategies to enhance detection of low abundance proteins in biomarker discovery studies.
Electrophoresis | 2002
Eugene C. Yi; Marcello Marelli; Hookeun Lee; Samuel O. Purvine; Ruedi Aebersold; John D. Aitchison; David R. Goodlett
We examined the utility of gas‐phase fractionation (GPF) in the m/z dimension to increase proteome coverage and reproducibility of peptide ion selection by direct microliquid chromatography/electrospray ionization‐tandem mass spectrometry (νLC/ESI‐MS/MS) analysis of the peptides produced by proteolytic digestion of unfractionated proteins from a yeast whole‐cell lysate and in a peroxisomal membrane protein fraction derived from isolated yeast peroxisomes. We also investigated GPF in the relative ion intensity dimension and propose denoting the two types of GPF as GPFm/z and GPFRI. Comparison of results of direct νLC/ESI‐MS/MS analysis of the unfractionated mixture of peptides from proteolysis of a yeast whole cell lysate by DD ion selection from 400–1800 m/z in triplicate and GPFm/z from 400–800, 800–1200 and 1200–1800 produced the following results: (i) 1.3× more proteins were identified by GPFm/z for an equal amount of effort (i.e., 3 νLC/ESI‐MS/MS) and (ii) proteins identified by GPFm/z had a lower average codon bias value. Use of GPFRI identified more proteins per m/z unit scanned than GPFm/z or triplicate analysis over a wide m/z range. After tryptic digestion of all the proteins from a discontinuous Nycodenz gradient fraction known to be enriched with yeast peroxisomal membrane proteins we detected 93% (38/41) of known peroxisomal proteins using GPFm/z, but only 73% using a standard wide m/z range survey scan.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Joshua F. Alfaro; Cheng Xin Gong; Matthew E. Monroe; Joshua T. Aldrich; Therese R. Clauss; Samuel O. Purvine; Zihao Wang; David G. Camp; Jeffrey Shabanowitz; Pamela Stanley; Gerald W. Hart; Donald F. Hunt; Feng Yang; Richard D. Smith
O-linked N-acetylglucosamine (O-GlcNAc) is a reversible posttranslational modification of Ser and Thr residues on cytosolic and nuclear proteins of higher eukaryotes catalyzed by O-GlcNAc transferase (OGT). O-GlcNAc has recently been found on Notch1 extracellular domain catalyzed by EGF domain-specific OGT. Aberrant O-GlcNAc modification of brain proteins has been linked to Alzheimers disease (AD). However, understanding specific functions of O-GlcNAcylation in AD has been impeded by the difficulty in characterization of O-GlcNAc sites on proteins. In this study, we modified a chemical/enzymatic photochemical cleavage approach for enriching O-GlcNAcylated peptides in samples containing ∼100 μg of tryptic peptides from mouse cerebrocortical brain tissue. A total of 274 O-GlcNAcylated proteins were identified. Of these, 168 were not previously known to be modified by O-GlcNAc. Overall, 458 O-GlcNAc sites in 195 proteins were identified. Many of the modified residues are either known phosphorylation sites or located proximal to known phosphorylation sites. These findings support the proposed regulatory cross-talk between O-GlcNAcylation and phosphorylation. This study produced the most comprehensive O-GlcNAc proteome of mammalian brain tissue with both protein identification and O-GlcNAc site assignment. Interestingly, we observed O-β-GlcNAc on EGF-like repeats in the extracellular domains of five membrane proteins, expanding the evidence for extracellular O-GlcNAcylation by the EGF domain-specific OGT. We also report a GlcNAc-β-1,3-Fuc-α-1-O-Thr modification on the EGF-like repeat of the versican core protein, a proposed substrate of Fringe β-1,3-N-acetylglucosaminyltransferases.
Proceedings of the National Academy of Sciences of the United States of America | 2003
Tina Guina; Samuel O. Purvine; Eugene C. Yi; Jimmy K. Eng; David R. Goodlett; Ruedi Aebersold; Samuel I. Miller
The opportunistic bacterial pathogen Pseudomonas aeruginosa colonizes airways of individuals with cystic fibrosis (CF) with resultant chronic destructive lung disease. P. aeruginosa adaptation to the CF airway includes biofilm formation and antibiotic resistance. Isolates from asymptomatic individuals in the first 3 years of life have unique characteristics, suggesting that adaptation occurs before clinical symptoms. One defined early adaptation is expression of a specific proinflammatory lipopolysaccharide (LPS) that is associated with antimicrobial peptide resistance. This CF-specific LPS is induced when P. aeruginosa is grown in medium that is limited for magnesium. Therefore, qualitative and quantitative proteomic approaches were used to define 1,331 P. aeruginosa proteins, of which 145 were differentially expressed on limitation of magnesium. Among proteins induced by low magnesium were enzymes essential for production of 2-heptyl 3-hydroxy 4-quinolone, the Pseudomonas quinolone signal (PQS), which interacts with the homoserine lactone signaling pathway. Measurement of PQS in P. aeruginosa isolates from asymptomatic children with CF indicated that strains with increased synthesis of PQS are present during early colonization of CF patient airways.
PLOS ONE | 2010
Steven E. Schutzer; Tao Liu; Benjamin H. Natelson; Thomas E. Angel; Athena A. Schepmoes; Samuel O. Purvine; Kim K. Hixson; Mary S. Lipton; David G. Camp; Patricia K. Coyle; Richard D. Smith; Jonas Bergquist
Background Knowledge of the entire protein content, the proteome, of normal human cerebrospinal fluid (CSF) would enable insights into neurologic and psychiatric disorders. Until now technologic hurdles and access to true normal samples hindered attaining this goal. Methods and Principal Findings We applied immunoaffinity separation and high sensitivity and resolution liquid chromatography-mass spectrometry to examine CSF from healthy normal individuals. 2630 proteins in CSF from normal subjects were identified, of which 56% were CSF-specific, not found in the much larger set of 3654 proteins we have identified in plasma. We also examined CSF from groups of subjects previously examined by others as surrogates for normals where neurologic symptoms warranted a lumbar puncture but where clinical laboratory were reported as normal. We found statistically significant differences between their CSF proteins and our non-neurological normals. We also examined CSF from 10 volunteer subjects who had lumbar punctures at least 4 weeks apart and found that there was little variability in CSF proteins in an individual as compared to subject to subject. Conclusions Our results represent the most comprehensive characterization of true normal CSF to date. This normal CSF proteome establishes a comparative standard and basis for investigations into a variety of diseases with neurological and psychiatric features.
Molecular & Cellular Proteomics | 2006
Tao Liu; Wei Jun Qiant; Marina A. Gritsenko; Wenzhong Xiao; Lyle L. Moldawer; Amit Kaushal; Matthew E. Monroe; Susan M. Varnum; Ronald J. Moore; Samuel O. Purvine; Ronald V. Maier; Ronald W. Davis; Ronald G. Tompkins; David G. Camp; Richard D. Smith; Henry V. Baker; Paul E. Bankey; Timothy R. Billiar; Bernard H. Brownstein; Steve E. Calvano; Celeste Campbell-Finnerty; George Casella; Irshad H. Chaudry; Mashkoor A. Choudhry; J. Perren Cobb; Asit De; Constance Elson; Bradley D. Freeman; Richard L. Gamelli; Nicole S. Gibran
Although human plasma represents an attractive sample for disease biomarker discovery, the extreme complexity and large dynamic range in protein concentrations present significant challenges for characterization, candidate biomarker discovery, and validation. Herein we describe a strategy that combines immunoaffinity subtraction and subsequent chemical fractionation based on cysteinyl peptide and N-glycopeptide captures with two-dimensional LC-MS/MS to increase the dynamic range of analysis for plasma. Application of this “divide-and-conquer” strategy to trauma patient plasma significantly improved the overall dynamic range of detection and resulted in confident identification of 22,267 unique peptides from four different peptide populations (cysteinyl peptides, non-cysteinyl peptides, N-glycopeptides, and non-glycopeptides) that covered 3654 different proteins with 1494 proteins identified by multiple peptides. Numerous low abundance proteins were identified, exemplified by 78 “classic” cytokines and cytokine receptors and by 136 human cell differentiation molecules. Additionally a total of 2910 different N-glycopeptides that correspond to 662 N-glycoproteins and 1553 N-glycosylation sites were identified. A panel of the proteins identified in this study is known to be involved in inflammation and immune responses. This study established an extensive reference protein database for trauma patients that provides a foundation for future high throughput quantitative plasma proteomic studies designed to elucidate the mechanisms that underlie systemic inflammatory responses.
Briefings in Functional Genomics and Proteomics | 2008
Charles Ansong; Samuel O. Purvine; Joshua N. Adkins; Mary S. Lipton; Richard D. Smith
While genome sequencing efforts reveal the basic building blocks of life, a genome sequence alone is insufficient for elucidating biological function. Genome annotation--the process of identifying genes and assigning function to each gene in a genome sequence--provides the means to elucidate biological function from sequence. Current state-of-the-art high-throughput genome annotation uses a combination of comparative (sequence similarity data) and non-comparative (ab initio gene prediction algorithms) methods to identify protein-coding genes in genome sequences. Because approaches used to validate the presence of predicted protein-coding genes are typically based on expressed RNA sequences, they cannot independently and unequivocally determine whether a predicted protein-coding gene is translated into a protein. With the ability to directly measure peptides arising from expressed proteins, high-throughput liquid chromatography-tandem mass spectrometry-based proteomics approaches can be used to verify coding regions of a genomic sequence. Here, we highlight several ways in which high-throughput tandem mass spectrometry-based proteomics can improve the quality of genome annotations and suggest that it could be efficiently applied during the gene calling process so that the improvements are propagated through the subsequent functional annotation process.